Viral vector-based therapeutic cancer vaccines
Open accessAbstract
Most viruses are naturally immunogenic and can be engineered to express tumor antigen transgenes. Moreover, many types of recombinant viruses have been shown to infect professional antigen-presenting cells, specifically dendritic cells, and express their transgenes. This enhanced presentation of tumor antigens to the immune system has led to an increase in the frequency and avidity of cytotoxic T lymphocytes that target tumor cells expressing the tumor antigen(s) encoded in the vaccine vector. Logistically, recombinant viruses can be produced, administered, and quality controlled more easily compared with other immunotherapy strategies. The intrinsic properties of each virus have distinct advantages and disadvantages, which can determine their applicability in a particular therapeutic setting. The disadvantage of some vectors is the development of host-induced neutralizing antibodies to the vector itself, thus limiting its continued use. The "off-the-shelf" nature of viral vaccine platforms renders them exceptionally suitable for multicenter randomized trials. This review described and discussed the strategies used and results using viral-based vaccines, with emphasis on phases II and III clinical trials. Future directions will involve the evaluation of viral-based vaccines in the adjuvant and neoadjuvant settings, in patients with low burden metastatic disease, and in combination with other forms of therapy including immunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The co-introduction of tumor antigens along with co-stimulatory molecules in a viral vector seems to be an even more effective way to trigger an effective immune response.
“Taking it a step forward, the co-introduction of tumor antigens along with co-stimulatory molecules in a viral vector seems to be an even more effective way to trigger an effective immune response [157].”
From Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy (2024) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Trends in Long-Term Survival Following Liver Resection for Hepatic Colorectal Metastases
Choti, M. A., Sitzmann, J. V., Tiburi, M. F., Sumetchotimetha, W., Rangsin, R., Schulick, R. D., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00002 · Cited by 1,456 · see citing works
Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andrès, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., et al. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000160703.75808.7d · Cited by 1,103 · see citing works
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glodé, L. M., Bilhartz, D. L., Wyand, M. S., Manson, K. H., Panicali, D., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 981 · see citing works
Self-citationHouse, M. G., Ito, H., Gönen, M., Fong, Y., Allen, P. J., DeMatteo, R. P., Brennan, M. F., Blumgart, L. H., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.040 · Cited by 517 · see citing works
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515 · see citing works
Tsang, K.-Y., Zaremba, S., Nieroda, C. A., Zhu, M., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498 · see citing works
Self-citationAntonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · see citing works
Gulley, J. L., Arlen, P. M., Bastian, A., Morin, S., Marté, J. L., Beetham, P. K., Tsang, K.-Y., Yokokawa, J., Hodge, J. W., Ménard, C. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2062 · Cited by 370 · see citing works
Self-citationPelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H. B., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 369 · see citing works
Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E. S., Pedicano, J. E., Gehan, E. A., Peck, R. A., Arlen, P. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 356 · see citing works
Self-citationAfonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3815-3831.2000 · Cited by 323 · see citing works
Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298 · see citing works
Self-citationGulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 296 · see citing works
Self-citationEder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294 · see citing works
Self-citationArlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M. P., Panicali, D., Beetham, P. K., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287 · see citing works
Self-citationVaccinia virus vaccines: Past, present and future
Jacobs, B. L., Langland, J., Kibler, K. V., Denzler, K. L., White, S. D., Holechek, S., Wong, S., Huynh, T. P., & Baskin, C. R. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.06.006 · Cited by 279 · see citing works
Vaccinia virus morphogenesis and dissemination
Roberts, K. L., & Smith, G. L. (2008) · Trends in Microbiology · doi:10.1016/j.tim.2008.07.009 · Cited by 278 · see citing works
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228 · see citing works
Self-citationKantor, J. A., Irvine, K. R., Abrams, S. I., Kaufman, H. L., Dipietro, J., & Schlom, J. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.14.1084 · Cited by 210 · see citing works
Self-citationRamlau, R., Quoix, É., Rolski, J., Pless, M., Léna, H., Lévy, E., Krzakowski, M. J., Hess, D., Tartour, É., Chenard, M., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31817c6b4f · Cited by 209 · see citing works
Amato, R. J., Hawkins, R. E., Kaufman, H. L., Thompson, J. A., Tomczak, P., Szczylik, C. A., McDonald, M., Eastty, S., Shingler, W. H., de Belin, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2082 · Cited by 199 · see citing works
Sutter, G., & Staib, C. (2003) · Current Drug Targets - Infectious Disorders · doi:10.2174/1568005033481123 · Cited by 191 · see citing works
Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2003) · Journal of Virology · doi:10.1128/jvi.78.1.353-366.2004 · Cited by 190 · see citing works
Kass, E. S., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., & Greiner, J. W. (1999) · PubMed · Cited by 176 · see citing works
Self-citationMeasles Virus for Cancer Therapy
Russell, S. J., & Peng, K.-W. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-70617-5_11 · Cited by 172 · see citing works
von Mehren, M., Arlen, P. M., Gulley, J. L., Rogatko, A., Cooper, H. S., Meropol, N. J., Alpaugh, R. K., Davey, M., McLaughlin, S. B., Beard, M., et al. (2001) · PubMed · Cited by 171 · see citing works
Self-citationHarrop, R., Connolly, N. B., Redchenko, I., Valle, J. W., Saunders, M. P., Ryan, M. G., Myers, K. A., Drury, N. L., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166 · see citing works
Gribben, J. G., Ryan, D. P., Boyajian, R. N., Urban, R. G., Hedley, M. L., Beach, K. J., Nealon, P., Matulonis, U. A., Campos, S. M., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165 · see citing works
von Mehren, M., Arlen, P. M., Tsang, K. Y., Rogatko, A., Meropol, N. J., Cooper, H. S., Davey, M. P., McLaughlin, S. B., Schlom, J., & Weiner, L. M. (2000) · PubMed · Cited by 156 · see citing works
Self-citationMadan, R. A., Gulley, J. L., Schlom, J., Steinberg, S. M., Liewehr, D. J., Dahut, W. L., & Arlen, P. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5048 · Cited by 150 · see citing works
Self-citationMultiple Costimulatory Modalities Enhance CTL Avidity
Hodge, J. W., Chakraborty, M., Kudo‐Saito, C., Garnett‐Benson, C., & Schlom, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.5994 · Cited by 138 · see citing works
Self-citationScholl, S., Balloul, J., Goc, G. L., Bizouarne, N., Schatz, C., Kiény, M. P., von Mensdorff‐Pouilly, S., Vincent‐Salomon, A., Deneux, L., Tartour, É., et al. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200009000-00007 · Cited by 129 · see citing works
Kass, E. S., Panicali, D., Mazzara, G. P., Schlom, J., & Greiner, J. W. (2001) · PubMed · Cited by 125 · see citing works
Self-citationClinical Safety of a Viral Vector Based Prostate Cancer Vaccine Strategy
Arlen, P. M., Skarupa, L., Pazdur, M. P., Seetharam, M., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., Poole, D. J., Litzinger, M. T., Steinberg, S. M., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.05.117 · Cited by 124 · see citing works
Self-citationCombination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer
Kaufman, H. L., Lenz, H., Marshall, J. L., Singh, D., Garrett, C. R., Cripps, C., Moore, M. J., von Mehren, M., Dalfen, R., Heim, W. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0276 · Cited by 122 · see citing works
Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data
Pesonen, S. A., Kangasniemi, L., & Hemminki, A. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100219n · Cited by 120 · see citing works
Arru, M., Aldrighetti, L. A., Castoldi, R., Palo, S. D., Orsenigo, E., Stella, M., Pulitanò, C., Gavazzi, F., Ferla, G., Carlo, V. D., et al. (2007) · World Journal of Surgery · doi:10.1007/s00268-007-9285-y · Cited by 120 · see citing works
Fowlpox virus as a vector in non-avian species
Taylor, J., & PAOLETTI, E. (1988) · Vaccine · doi:10.1016/0264-410x(88)90091-6 · Cited by 118 · see citing works
Morse, M. A., Hobeika, A. C., Osada, T., Berglund, P., Hubby, B., Negri, S., Niedzwiecki, D., Devi, G. R., Burnett, B. K., Clay, T. M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42672 · Cited by 118 · see citing works
Selective Induction of High Avidity CTL by Altering the Balance of Signals from APC
Oh, S., Hodge, J. W., Ahlers, J. D., Burke, D. S., Schlom, J., & Berzofsky, J. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2523 · Cited by 116 · see citing works
Self-citationTargeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+ and CD8+ T Cells
Bonini, C., Lee, S. P., Riddell, S., & Greenberg, P. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.5250 · Cited by 113 · see citing works
Bridle, B. W., Boudreau, J. E., Lichty, B. D., Brunellière, J., Stephenson, K. B., Koshy, S. T., Bramson, J. L., & Wan, Y. (2009) · Molecular Therapy · doi:10.1038/mt.2009.154 · Cited by 111 · see citing works
Somogyi, P., Frazier, J. A., & Skinner, M. A. (1993) · Virology · doi:10.1006/viro.1993.1608 · Cited by 109 · see citing works
Oudard, S. M., Rixe, O., Beuselinck, B., Linassier, C., Banu, E., Machiels, J.-P., Baudard, M., Ringeisen, F. P., Velu, T. J., Frère‐Belda, M. L., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0935-9 · Cited by 109 · see citing works
Arlen, P. M., Gulley, J. L., Todd, N., Lieberman, R., Steinberg, S. M., MORIN, S., Bastian, A., Marté, J. L., Tsang, K.-Y., Beetham, P. K., et al. (2005) · The Journal of Urology · doi:10.1097/01.ju.0000165159.33772.5b · Cited by 108 · see citing works
Self-citationAarts, W. M., Schlom, J., & Hodge, J. W. (2002) · PubMed · Cited by 98 · see citing works
Self-citationDrillien, R., Spehner, D., Bohbot, A., & Hanau, D. (2000) · Virology · doi:10.1006/viro.2000.0203 · Cited by 96 · see citing works
Harrop, R., Drury, N. L., Shingler, W. H., Chikoti, P., Redchenko, I., Carroll, M. W., Kingsman, S. M., Naylor, S., Melcher, A. A., Nicholls, J. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0704 · Cited by 90 · see citing works
Kündig, T. M., Kalberer, C. P., Hengartner, H., & Zinkernagel, R. M. (1993) · Vaccine · doi:10.1016/0264-410x(93)90079-d · Cited by 90 · see citing works
Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Güller, U., Noppen, C., Padovan, E., Schultz‐Thater, E., Heberer, M., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322495016 · Cited by 90 · see citing works
PANVAC™-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Madan, R. A., Arlen, P. M., & Gulley, J. L. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.4.543 · Cited by 89 · see citing works
Alphavirus vectors: development and potential therapeutic applications
Schlesinger, S. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.2.177 · Cited by 88 · see citing works
Harrop, R., Drury, N. L., Shingler, W. H., Chikoti, P., Redchenko, I., Carroll, M. W., Kingsman, S. M., Naylor, S., Griffiths, R., Steven, N. M., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0428-7 · Cited by 85 · see citing works
Dreicer, R., Stadler, W. M., Ahmann, F. R., Whiteside, T. L., Bizouarne, N., Acres, B., Limacher, J., Squiban, P. J., & Pantuck, A. J. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9187-3 · Cited by 79 · see citing works
Pastoret, P.-P., & Vanderplasschen, A. (2003) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/s0147-9571(03)00019-5 · Cited by 79 · see citing works
Li, N., Zhou, J., Weng, D., Zhang, C., Li, L., Wang, B., Song, Y., He, Q., Lin, D., Chen, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0499 · Cited by 79 · see citing works
Amato, R. J., Shingler, W. H., Goonewardena, M., de Belin, J., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ace876 · Cited by 78 · see citing works
Kaufman, H. L., Cohen, S., Cheung, K., DeRaffele, G., Mitcham, J., Moroziewicz, D. N., Schlom, J., & Hesdorffer, C. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.239 · Cited by 77 · see citing works
Self-citationKaufman, H. L., Taback, B., Sherman, W. H., Kim, D. W., Shingler, W. H., Moroziewicz, D. N., DeRaffele, G., Mitcham, J., Carroll, M. W., Harrop, R., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-2 · Cited by 75 · see citing works
Anderson, P. M., & NUÑEZ, R. F. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.11.1517 · Cited by 72 · see citing works
Alphavirus vectors for cancer therapy
Quetglas, J. I., Ruiz-Guillen, M., Aranda, A., Casales, E., Bezunartea, J., & Smerdou, C. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.027 · Cited by 72 · see citing works
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer
Myers, R. M., Greiner, S. M., Harvey, M. E., Soeffker, D., Frenzke, M. E., Abraham, K. G., SHAW, A. R., Rozenblatt, S., Federspiel, M. J., Russell, S. J., et al. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700823 · Cited by 68 · see citing works
Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges
Galanis, E. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.211 · Cited by 66 · see citing works
Andrès, A., Majno, P. E., Morel, P., Rubbia‐Brandt, L., Giostra, E., Gervaz, P., Terraz, S., Allal, A. S., Roth, A. D., & Mentha, G. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9607-1 · Cited by 62 · see citing works
Amato, R. J., Shingler, W. H., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J., & Harrop, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0668 · Cited by 62 · see citing works
Use of attenuated paramyxoviruses for cancer therapy
Lech, P. J., & Russell, S. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.124 · Cited by 58 · see citing works
Amato, R. J., Drury, N. L., Naylor, S., Jac, J., Saxena, S., Cao, A., Hernandez-McClain, J., & Harrop, R. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817deafd · Cited by 55 · see citing works
Lindsey, K. R., Gritz, L. R., Sherry, R. M., Abati, A. D., Fetsch, P. A., Goldfeder, L. C., Gonzales, M. I., Zinnack, K., Rogers-Freezer, L. J., Haworth, L. R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2061 · Cited by 50 · see citing works
Spaner, D., Astsaturov, I. A., Vogel, T. U., Petrella, T. M., Elias, I., Burdett‐Radoux, S., Verma, S., Iscoe, N., Hamilton, P., & Berinstein, N. L. (2006) · Cancer · doi:10.1002/cncr.21669 · Cited by 49 · see citing works
Elkord, E., Dangoor, A., Drury, N. L., Harrop, R., Burt, D. J., Drijfhout, J. W., Hamer, C., Andrews, D., Naylor, S., Sherlock, D., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181876ab3 · Cited by 48 · see citing works
Hawkins, R. E., Macdermott, C., Shablak, A., Hamer, C., Thistlethwaite, F. C., Drury, N. L., Chikoti, P., Shingler, W. H., Naylor, S., & Harrop, R. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819d297e · Cited by 43 · see citing works
Perera, L. P., Waldmann, T. A., Mosca, J. D., Baldwin, N. E., Berzofsky, J. A., & Oh, S. (2007) · Journal of Virology · doi:10.1128/jvi.00538-07 · Cited by 43 · see citing works
Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors
Brown, M. D., Davies, D. H., Skinner, M. A., Bowen, G. P., Hollingsworth, S. J., Mufti, G. J., Arrand, J. R., & Stacey, S. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700014 · Cited by 42 · see citing works
Yang, S., Tsang, K.-Y., & Schlom, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0670 · Cited by 41 · see citing works
Self-citationArlen, P. M., Pazdur, M. P., Skarupa, L., Rauckhorst, M., & Gulley, J. L. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.032 · Cited by 40 · see citing works
Arlen, P. M., Kaufman, H. L., & DiPaola, R. S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.006 · Cited by 40 · see citing works
Engineered adenovirus serotypes for overcoming anti-vector immunity
Dharmapuri, S., Peruzzi, D., & Aurisicchio, L. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903187053 · Cited by 38 · see citing works
Oncolytic Herpes Viruses as a Potential Mechanism for Cancer Therapy
Lou, E. (2003) · Acta Oncologica · doi:10.1080/0284186031000518 · Cited by 34 · see citing works
Reali, E., Canter, D. J., Zeytin, H. E., Schlom, J., & Greiner, J. W. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.11.060 · Cited by 32 · see citing works
Self-citationPalena, C., Zhu, M., Schlom, J., & Tsang, K.-Y. (2004) · Blood · doi:10.1182/blood-2003-09-3211 · Cited by 29 · see citing works
Self-citationAdvances in viral-vector systemic cytokine gene therapy against cancer
Liu, L., Wang, S., Shan, B., Sang, M., Liu, S., & Wang, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.041 · Cited by 28 · see citing works
Litzinger, M. T., Foon, K. A., Sabzevari, H., Tsang, K.-Y., Schlom, J., & Palena, C. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0611-5 · Cited by 23 · see citing works
Self-citationKudo‐Saito, C., Wansley, E. K., Gruys, M. E., Wiltrout, R. H., Schlom, J., & Hodge, J. W. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2398 · Cited by 23 · see citing works
Self-citationKudo‐Saito, C., Garnett‐Benson, C., Wansley, E. K., Schlom, J., & Hodge, J. W. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0332-1 · Cited by 16 · see citing works
Self-citationPotential of Alphavirus Vectors in the Treatment of Advanced Solid Tumors
Kelly, B., Fleeton, M. N., & Atkins, G. J. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207780832432 · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [38]Grosenbach DW Feldman J Schlom J Kaufman H Wolchok JD Recombinant viral and bacterial vaccines General Principles of Tumor Immunotherapy: Basic and CLinical Applications of Tumor Immunology The Netherlands Springer 2008 217 250
- [55]DiPaola RS Chen Y Bubley GJ A Phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: results of ECOG 9802 abstr 108 2009 ASCO Genitourinary Cancers Symposium
- [61]Bilusic M Gulley J Heery C A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer J Clin Oncol 2011 suppl 7 abstr 163 2011 ASCO Genitourinary Cancer Symposium
- [65]Petrylak D Defining the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive sipuleucel-T (PROVENGE) followed by docetaxel derive greatest survival benefit 14th Annual Meeting of the Chemotherapy Foundation Symposium New York, NY November 8–11, 2006
Cited by
Sorted by citations
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869 · see citing works
Integrating oncolytic viruses in combination cancer immunotherapy
Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704 · see citing works
Turning the corner on therapeutic cancer vaccines
Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689 · see citing works
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546 · see citing works
Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 520 · see citing works
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 424 · see citing works
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J. Y., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 314 · see citing works
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 285 · see citing works
The dawn of vaccines for cancer prevention
Finn, O. J. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.140 · Cited by 254 · see citing works
Human Tumor Antigens and Cancer Immunotherapy
Vigneron, N. (2015) · BioMed Research International · doi:10.1155/2015/948501 · Cited by 227 · see citing works
Best practices for bioinformatic characterization of neoantigens for clinical utility
Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 212 · see citing works
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 212 · see citing works
Cancer Vaccines, Adjuvants, and Delivery Systems
Paston, S. J., Brentville, V. A., Symonds, P., & Durrant, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.627932 · Cited by 200 · see citing works
Impact of the immune system and immunotherapy in colorectal cancer.
Markman, J. L., & Shiao, S. L. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.077 · Cited by 196 · see citing works
mRNA vaccines for cancer immunotherapy
Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1029069 · Cited by 180 · see citing works
Wood, L. M., & Paterson, Y. Y. W. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 158 · see citing works
Morse, M. A., Niedzwiecki, D., Marshall, J. L., Garrett, C. H., Chang, D. Z., Aklilu, M., Crocenzi, T. S., Cole, D. J., Dessureault, S., Hobeika, A. C., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318292919e · Cited by 142 · see citing works
New viral vectors for infectious diseases and cancer
Sasso, E., D’Alise, A. M., Zambrano, N., Scarselli, E., Folgori, A., & Nicosia, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101430 · Cited by 120 · see citing works
Engineered materials for cancer immunotherapy
Cheung, A. S., & Mooney, D. J. (2015) · Nano Today · doi:10.1016/j.nantod.2015.06.007 · Cited by 107 · see citing works
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 105 · see citing works
Schlom, J., Hodge, J. W., Palena, C., Tsang, K.-Y., Jochéms, C., Greiner, J. W., Farsaci, B., Madan, R. A., Heery, C. R., & Gulley, J. L. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00002-0 · Cited by 102 · see citing works
Self-citationAdvances in gene-based vaccine platforms to address the COVID-19 pandemic
Pushparajah, D., Jimenez, S., Wong, S. L., Alattas, H., Nafissi, N., & Slavcev, R. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.003 · Cited by 98 · see citing works
Immunotherapy for colorectal cancer
Koido, S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8531 · Cited by 86 · see citing works
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 83 · see citing works
Therapeutic vaccines for breast cancer: Has the time finally come?
Corti, C., Giachetti, P. P. M. B., Eggermont, A. M. M., Delaloge, S., & Curigliano, G. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.10.027 · Cited by 84 · see citing works
Advances in immunotherapy for the treatment of glioblastoma
Tivnan, A., Heilinger, T., Lavelle, E. C., & Prehn, J. H. M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2299-2 · Cited by 83 · see citing works
Senovilla, L., Vacchelli, E., Garcia, P., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23803 · Cited by 81 · see citing works
Immunotherapeutic approaches to ovarian cancer treatment
Chester, C., Dorigo, O., Berek, J. S., & Kohrt, H. E. K. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0051-7 · Cited by 80 · see citing works
Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 81 · see citing works
Nanovaccines: An effective therapeutic approach for cancer therapy
Gurunathan, S., Pratheep, T., Wang, L., Cao, Q., & Kim, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115992 · Cited by 76 · see citing works
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76 · see citing works
Clinical applications of attenuated MVA poxvirus strain
Gómez, C. E., Perdiguero, B., García‐Arriaza, J., & Estéban, M. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.845531 · Cited by 73 · see citing works
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 70 · see citing works
Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches
Davodabadi, F., Sarhadi, M., Arabpour, J., Sargazi, S., Rahdar, A., & Diez-Pascual, A. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.036 · Cited by 73 · see citing works
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines
Oladejo, M., Paulishak, W., & Wood, L. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.003 · Cited by 74 · see citing works
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 72 · see citing works
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 76 · see citing works
Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment
Dewitte, H., Verbeke, R., Breckpot, K., Smedt, S. C. D., & Lentacker, I. (2014) · Nano Today · doi:10.1016/j.nantod.2014.10.001 · Cited by 71 · see citing works
Microneedles: an innovative platform for gene delivery
McCaffrey, J., Donnelly, R. F., & McCarthy, H. O. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0243-1 · Cited by 69 · see citing works
The Effects of Pre-Existing Antibodies on Live-Attenuated Viral Vaccines
Mok, D. Z. L., & Chan, K. R. (2020) · Viruses · doi:10.3390/v12050520 · Cited by 68 · see citing works
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
Antonarelli, G., Corti, C., Tarantino, P., Ascione, L., Cortés, J., Romero, P. J., Mittendorf, E., Disis, M. L., & Curigliano, G. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2153 · Cited by 63 · see citing works
Colorectal cancer vaccines: The current scenario and future prospects
Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62 · see citing works
Peptide Hydrogels as Immunomaterials and Their Use in Cancer Immunotherapy Delivery
Falcone, N., Ermis, M., Tamay, D. G., Mecwan, M. M., Monirizad, M., Mathes, T. G., Jucaud, V., Choroomi, A., de Barros, N. R., Zhu, Y., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202301096 · Cited by 58 · see citing works
Ruiu, R., Rolih, V., Bolli, E., Barutello, G., Riccardo, F., Quaglino, E., Merighi, I. F., Pericle, F., Donofrío, G., Cavallo, F., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2185-1 · Cited by 52 · see citing works
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives
Agostinetto, E., Montemurro, F., Puglisi, F., Criscitiello, C., Bianchini, G., Mastro, L. D., Introna, M., Tondini, C. A., Santoro, A., & Zambelli, A. (2022) · Cancers · doi:10.3390/cancers14092136 · Cited by 51 · see citing works
Exosome-based immunotherapy as an innovative therapeutic approach in melanoma
Babaei, S., Fadaee, M., Abbasi‐Kenarsari, H., Shanehbandi, D., & Kazemi, T. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01906-1 · Cited by 49 · see citing works
Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines
Šošić, L., Selbo, P. K., Kotkowska, Z. K., Kündig, T. M., Høgset, A., & Johansen, P. (2020) · Cancers · doi:10.3390/cancers12010165 · Cited by 46 · see citing works
Immunotherapy in ovarian cancer
Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 48 · see citing works
Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine
Belnoue, E., Mayol, J.-F., Carboni, S., Berardino-Besson, W. D., Dupuychaffray, E., Nelde, A., Stevanović, S., Santiago‐Raber, M., Walker, P. R., & Derouazi, M. (2019) · JCI Insight · doi:10.1172/jci.insight.127305 · Cited by 46 · see citing works
Anti-Colorectal Cancer Effects of Probiotic-Derived p8 Protein
An, B. C., Hong, S., Park, H. J., Kim, B.-K., Ahn, J. Y., Ryu, Y., An, J. H., & Chung, M. J. (2019) · Genes · doi:10.3390/genes10080624 · Cited by 44 · see citing works
Zhang, L., Bridle, B. W., Chen, L., Pol, J. G., Spaner, D., Boudreau, J. E., Rosen, A., Bassett, J. D., Lichty, B. D., Bramson, J. L., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438481 · Cited by 43 · see citing works
Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses
Murthy, V., Minehart, J. C., & Sterman, D. H. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx097 · Cited by 43 · see citing works
Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force
Wang, Z., Zhi, K., Ding, Z., Sun, Y., Li, S., Li, M., Pu, K., & Zou, J. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.012 · Cited by 42 · see citing works
Conti, L., Bolli, E., Lorenzo, A. D., Franceschi, V., Macchi, F., Riccardo, F., Ruiu, R., Russo, L., Quaglino, E., Donofrío, G., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0082 · Cited by 42 · see citing works
Beiss, V., Mao, C., Fiering, S., & Steinmetz, N. F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00058 · Cited by 40 · see citing works
Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy
Shanmugaraj, B., Priya, L. B., Mahalakshmi, B., Subbiah, S., Hu, R., Velmurugan, B. K., & Baskaran, R. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117550 · Cited by 39 · see citing works
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy
Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works
Dafni, U., Lluesma, S. M., Balint, K., Tsourti, Z., Vervita, K., Chenal, J., Coukos, G., Zaman, K., Sarivalasis, A., & Kandalaft, L. E. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.10.014 · Cited by 38 · see citing works
Recent progress in cancer vaccines and nanovaccines
Poudel, K., Vithiananthan, T., Kim, J. O., & Tsao, H. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122856 · Cited by 40 · see citing works
Boosting CAR-T cell therapy through vaccine synergy
Li, Y.-R., Lyu, Z., Shen, X., Fang, Y., & Yang, L. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.004 · Cited by 38 · see citing works
Recombinant Viruses for Cancer Therapy
Chulpanova, D. S., Solovyeva, V. V., Kitaeva, K. V., Dunham, S. P., Khaiboullina, S. F., & Rizvanov, A. A. (2018) · Biomedicines · doi:10.3390/biomedicines6040094 · Cited by 37 · see citing works
Håkerud, M., Selbo, P. K., Waeckerle‐Men, Y., Contassot, E., Dziunycz, P., Kündig, T. M., Høgset, A., & Johansen, P. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.032 · Cited by 36 · see citing works
Breast cancer vaccination comes to age: impacts of bioinformatics
Parvizpour, S., Razmara, J., & Omidi, Y. (2018) · Bioimpacts · doi:10.15171/bi.2018.25 · Cited by 36 · see citing works
Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy
Bou-Dargham, M. J., Draughon, S. A., Cantrell, V., Khamis, Z. I., & Sang, Q. A. (2021) · Journal of Cancer · doi:10.7150/jca.64205 · Cited by 37 · see citing works
Trial watch: Naked and vectored DNA-based anticancer vaccines
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Sautès‐Fridman, C., Fucikova, J. P., Galon, J., Špíšek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026531 · Cited by 35 · see citing works
Replicating poxviruses for human cancer therapy
Kim, M. (2015) · The Journal of Microbiology · doi:10.1007/s12275-015-5041-4 · Cited by 35 · see citing works
Olsen, H. E., Lynn, G. M., Valdes, P. A., Cerecedo-Lopez, C. D., Ishizuka, A. S., Arnaout, O. M., Bi, W. L., Peruzzi, P. P., Chiocca, E. A., Friedman, G. K., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab027 · Cited by 35 · see citing works
Kim, S., Park, A. K., Chaurasiya, S., Kang, S., Lü, J., Yang, A., Sivanandam, V., Zhang, Z., Woo, Y., Priceman, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0405 · Cited by 34 · see citing works
Targeting Glioblastoma: The Current State of Different Therapeutic Approaches
Khan, I., Mahfooz, S., Elbasan, E. B., Karaçam, B., Öztanır, M. N., & Hatiboğlu, M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210113152108 · Cited by 34 · see citing works
Berry, J., Vreeland, T. J., Trappey, A. F., Hale, D. F., Peace, K. M., Tyler, J. A., Walker, A. S., Brown, R. A., Herbert, G. S., Yi, F., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1226132 · Cited by 34 · see citing works
Engaging Natural Killer T Cells as ‘Universal Helpers’ for Vaccination
Speir, M., Hermans, I. F., & Weinkove, R. (2016) · Drugs · doi:10.1007/s40265-016-0675-z · Cited by 33 · see citing works
Viral gene delivery vectors: the next generation medicines for immune-related diseases
De Haan, P., Van Diemen, F. R., & Toscano, M. G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1757989 · Cited by 34 · see citing works
Palma, M. (2025) · Vaccines · doi:10.3390/vaccines13040344 · Cited by 33 · see citing works
Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics
Le, I., Dhandayuthapani, S., Chacon, J. A., Eiring, A. M., & Gadad, S. S. (2022) · Vaccines · doi:10.3390/vaccines10050816 · Cited by 32 · see citing works
Mohit, E., & Rafati, S. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.005 · Cited by 31 · see citing works
Bonilla, W. V., Kirchhammer, N., Marx, A., Kallert, S. M., Krzyzaniak, M. A., Lu, M., Darbre, S., Schmidt, S., Raguz, J., Berka, U., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100209 · Cited by 31 · see citing works
The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02052 · Cited by 27 · see citing works
Chemokine-Based Immunotherapy: Delivery Systems and Combination Therapies
Mohit, E., & Rafati, S. (2012) · Immunotherapy · doi:10.2217/imt.12.72 · Cited by 30 · see citing works
Erkes, D. A., Xu, G., Daskalakis, C., Zurbach, K. A., Wilski, N. A., Moghbeli, T., Hill, A. B., & Snyder, C. M. (2016) · Molecular Therapy · doi:10.1038/mt.2016.121 · Cited by 30 · see citing works
Altenburg, A. F., Trierum, S. E. V.-V., de Bruin, E., de Meulder, D., van de Sandt, C. E., van der Klis, F. R. M., Fouchier, R. A. M., Koopmans, M., Rimmelzwaan, G. F., & de Vries, R. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-24820-2 · Cited by 30 · see citing works
Viroimmunotherapy for Colorectal Cancer: Clinical Studies
Chaurasiya, S., & Warner, S. G. (2017) · Biomedicines · doi:10.3390/biomedicines5010011 · Cited by 28 · see citing works
Han, S. R., Lee, C. H., Im, J. Y., Kim, J. H., Kim, J. H., Kim, S. J., Cho, Y. W., Kim, E., Kim, Y., Ryu, J.-H., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.10.036 · Cited by 28 · see citing works
mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27 · see citing works
A new era of cancer immunotherapy: vaccines and miRNAs
Sareen, G., Mohan, M., Mannan, A., Dua, K., & Singh, T. G. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04011-5 · Cited by 26 · see citing works
Immunotherapy in prostate cancer: review of the current evidence
Fernández‐García, E. M., Vera-Badillo, F., Pérez‐Valderrama, B., Matos-Pita, A. S., & Durán, I. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1259-6 · Cited by 26 · see citing works
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 26 · see citing works
Harao, M., Mittendorf, E. A., & Radvanyi, L. G. (2014) · BioDrugs · doi:10.1007/s40259-014-0114-1 · Cited by 25 · see citing works
Personal Neoantigen Vaccines for the Treatment of Cancer
Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 26 · see citing works
The role of viruses in cancer development versus cancer therapy: An oncological perspective
Javid, H., Mashhad, A. S., Yazdani, S., Oryani, M. A., Akbari, S., Rezagholinejad, N., Tajaldini, M., & Karimi‐Shahri, M. (2023) · Cancer Medicine · doi:10.1002/cam4.5694 · Cited by 24 · see citing works
Rowe, J. H., & Cen, P. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.973323 · Cited by 25 · see citing works
Huang, C., Ramakrishnan, R., Trkulja, M., Ren, X., & Gabrilovich, D. I. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1198-9 · Cited by 25 · see citing works
Han, Y.-J., Shao, C.-Y., Yao, Y., Zhang, Z., Fang, M., Gong, T., Zhang, Y., & Li, M. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad136 · Cited by 25 · see citing works
Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer
Allahverdiyev, A., Tari, G., Bağırova, M., & Abamor, E. Ş. (2018) · Journal of Breast Cancer · doi:10.4048/jbc.2018.21.e47 · Cited by 25 · see citing works
Protein-driven nanomedicines in oncotherapy
Casanova, I., Unzueta, U., Arroyo‐Solera, I., Céspedes, M. V., Villaverde, A., Mangues, R., & Vázquez, E. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.12.004 · Cited by 24 · see citing works
Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment
Dhas, N. L., Kudarha, R. R., Kulkarni, S., Soman, S., Navti, P. D., Kulkarni, J., Roy, A. A., Colaco, V., Raychaudhuri, R., Gupta, A., et al. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2910349 · Cited by 23 · see citing works
Vasiļevska, J., Skrastiņa, D., Spunde, K., Garoff, H., Kozlovska, T., & Zajakina, A. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.37 · Cited by 23 · see citing works
Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor
Xie, Y., Liu, W.-Q., Li, D., Hou, J.-C., Coghi, P. S., & Fan, X. (2023) · Vaccines · doi:10.3390/vaccines11020394 · Cited by 22 · see citing works
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22 · see citing works
Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 20 · see citing works
Wan, Y., Simovic, B., & Walsh, S. R. (2015) · Oncolytic Virotherapy · doi:10.2147/ov.s66079 · Cited by 20 · see citing works
- Authors
- Larocca, C., & Schlom, J.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- Corresponding author
- Larocca, Cecilia
- Venue
- The Cancer Journal
- Published
- 2011-09
- Volume
- 17
- Issue
- 5
- Pages
- 359-371
- ISSN
- 1528-9117 (ISSN-L)
- PMC
- PMC3207353
- OpenAlex
- W2076096828
- Cited by
- 222
- References
- 85
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 25 · 2023: 21 · 2022: 16 · 2021: 20 · 2020: 16 · 2019: 10 · 2018: 14 · 2017: 9 · 2016: 9 · 2015: 17 · 2014: 17 · 2013: 15 · 2012: 5
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Cancer Journal (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health
- National Cancer Institute (ZIABC010425)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
- Keywords
- viral vector vaccines, therapeutic cancer vaccines, dendritic cells, antigen presentation, cytotoxic T lymphocytes, neutralizing antibodies, recombinant virus, neoadjuvant and adjuvant therapy, metastatic cancer, combination immunotherapy, clinical trials
- MeSH terms
- Antigens, Neoplasm, Clinical Trials as Topic, Genetic Vectors, Humans, Male, Prostatic Neoplasms, Viral Vaccines, Viruses, Vaccines, DNA, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
